ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,297.10
-0.21%
US Tech 100
18,079.20
0.00%
Dow Jones
39,869.38
-0.10%
Brent Oil
83.385
0.22%
Bitcoin
66,347.51
1.70%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX
  6. Eupraxia Pharmaceuticals Inc (EPRX)

  7. Eupraxia Pharmaceuticals Inc (EPRX) News

EPRX

Eupraxia Pharmaceuticals (EPRX)

Eupraxia Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:TSX:EPRX
DateTimeSourceHeadlineSymbolCompany
05/14/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/14/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024TSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20245:03PMPR Newswire (US)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/08/20245:03PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
05/02/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardTSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/11/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/08/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20247:00AMPR Newswire (US)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/05/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Begins Trading on Nasdaq TodayTSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/03/20245:00PMPR Newswire (US)Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024TSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20245:01PMPR Newswire (US)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
04/01/20245:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20249:41AMPR Newswire (Canada)L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/12/20249:39AMPR Newswire (Canada)Canadian Investment Regulatory Organization Trade Resumption - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/11/20244:06PMPR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
03/11/20244:04PMPR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - EPRXTSX:EPRXEupraxia Pharmaceuticals Inc
02/05/20245:00PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Updated Positive Clinical Data in EP-104GI RESOLVE Trial for the Treatment of Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
02/01/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Initiates Phase 3 Development Program for EP-104IARTSX:EPRXEupraxia Pharmaceuticals Inc
01/30/20247:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Data from MRI Exploratory Sub-Study in Phase 2 SPRINGBOARD Trial Evaluating the Safety and Efficacy of EP-104IAR for the Treatment of Osteoarthritis of the KneeTSX:EPRXEupraxia Pharmaceuticals Inc
01/08/20246:44PMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Filing of Preliminary MJDS Base Shelf ProspectusTSX:EPRXEupraxia Pharmaceuticals Inc
12/12/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Positive Clinical Data in EP-104GI RESOLVE TrialTSX:EPRXEupraxia Pharmaceuticals Inc
12/11/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Clinical and Corporate UpdateTSX:EPRXEupraxia Pharmaceuticals Inc
11/14/20235:01PMPR Newswire (Canada)Eupraxia Pharmaceuticals Reports Third Quarter 2023 Financial ResultsTSX:EPRXEupraxia Pharmaceuticals Inc
11/01/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the 2023 Annual Meeting of the American College of RheumatologyTSX:EPRXEupraxia Pharmaceuticals Inc
10/11/20237:00AMPR Newswire (Canada)Eupraxia Pharmaceuticals Announces Initiation of Second Cohort in Phase 1b/2a Clinical Trial in Eosinophilic EsophagitisTSX:EPRXEupraxia Pharmaceuticals Inc
09/11/20233:32PMPR Newswire (Canada)Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceTSX:EPRXEupraxia Pharmaceuticals Inc
 Showing the most relevant articles for your search:TSX:EPRX

Your Recent History

BIT
P1CN03
BNP Paribas Issuance
USOTC
SSTMF
SPDR Straits Times Index... (GM)
BOV
ELETQ335
ELETQ335 Ex:33,1
BIT
S30562
Societe Generale Effekten
BIT
S27015
Societe Generale Effekten
BIT
S30560
Societe Generale Effekten
BIT
S24883
SG ISSUER
BIT
P10QU6
Bnp Paribas Issuance
BIT
AED
Aedes SIIQ
BIT
P1BVV1
BNP Paribas Issuance
BIT
I05815
Banca Imi
NYSE
MNR.PRC
Monmouth Real Estate Investment
BIT
PRI
Prima Industrie
NYSE
HJD
Morgan Stanley Str Saturns AT &
BIT
F28621
Vontobel Financial Produ...
BIT
S27447
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved